Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: bob zagorin who wrote (23873)	8/4/1998 7:13:00 AM
From: Henry Niman	Respond to of 32384

bob, I not sure if that change affect LGND directly or nor. At the end of last year's 3Q the T Rowe Price Health Sciences fund owned 125,000 shares of LGND: www3.techstocks.com However, in total, T Rowe Price owned 438,000 shares, down from over 638,000 shares: www3.techstocks.com Anyone have more recent numbers?

To: bob zagorin who wrote (23873)	8/4/1998 8:19:00 AM
From: Henry Niman	Respond to of 32384

Speaking of news, a report on Bone Fracture prevention by low dose Tamoxifen just came out: paradise-web.com As you know, Targretin and Panretin synergize with Tamoxifen.

To: bob zagorin who wrote (23873)	8/4/1998 3:20:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

bob, I checked with LGND IR today, and it doesn't sound like LGND was directly affected by changes a T. Rowe Price. The family of funds has owned quite a bit of LGND for some time now and there has been little change in their position over the past several months. As I posted previously, at the end of last year's 3Q they held over 400,000 shares of LGND. As of a few weeks ago, their holdings were even higher. The WSJ article confirmed what I had heard elsewhere. The big boys are pulling out of the smaller Biotechs. Companies like LGND, with products in late stages of development should eventually benefit, although at this time the Biotech glass clearly has a "half empty" look.